Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial looking at irinotecan with or without cetuximab for bowel cancer that has spread (EPIC EMR 622202 - 025)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial looked at irinotecan with or without cetuximab (Erbitux) for people with advanced bowel cancer.
Cetuximab is a type of biological therapy called a monoclonal antibody. Some cancer cells have receptors on the cell surface called epidermal growth factor receptors, or EGFRs. When the epidermal growth factor (EGF) attaches to the receptor, it triggers the cancer cell to keep growing. Cetuximab attaches itself to the receptor instead, and stops this process.
In this trial, some people had irinotecan and cetuximab, and some had irinotecan alone.
The aims of this trial were to find out
- If irinotecan and cetuximab is better for bowel cancer that has spread than irinotecan alone
- More about the side effects
- What effect it had on quality of life
Summary of results
The research team found that cetuximab and irinotecan is better for advanced bowel cancer than irinotecan alone.
This trial recruited 1,298 people with bowel cancer that had spread and whose cancer had been tested to see if the cells had EGFRs. They had all had chemotherapy before, but their cancer had continued to grow. Of these 1,298 people,
- 650 had irinotecan alone
- 648 had irinotecan and cetuximab
The research team looked at how many people’s cancer responded to treatment. They found it was
- Just over 4 out of 100 people (4.2%) who had irinotecan alone
- Over 16 out of every 100 people (16.4%) who had irinotecan and cetuximab
They also found that the cancer stopped growing for longer when people had both treatments.
When they looked at how long people had lived overall, they found the 2 groups were similar. But this could be because of treatment they had after the trial. Nearly half of the people who had irinotecan alone on the trial went on to have cetuximab at a later date.
The research team also looked at the effect treatment had on quality of life. They found that quality of life was similar for both groups at the start of the trial. Although it dropped a bit for both groups after treatment, the group that had irinotecan and cetuximab had a better quality of life than the group that had irinotecan alone. In particular, they had less pain and sickness.
The research team concluded it was useful to add cetuximab to irinotecan for advanced bowel cancer. And that it affected quality of life less than irinotecan alone.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Professor D. Cunningham